Literature DB >> 32077410

Risk Factors for Withdrawal of Life-Sustaining Treatment in Severe Traumatic Brain Injury.

Sahil Gambhir1, Areg Grigorian1, Divya Ramakrishnan1, Catherine M Kuza2, Brian Sheehan1, Shelley Maithel1, Jeff Nahmias1.   

Abstract

Studies demonstrate a significant variation in decision-making regarding withdrawal of life-sustaining treatment (WLST) practices for patients with severe traumatic brain injury (TBI). We investigated risk factors associated with WLST in severe TBI. We hypothesized age ≥65 years would be an independent risk factor. In addition, we compared survivors with patients who died in hospital after WLST to identify potential factors associated with in-hospital mortality. The Trauma Quality Improvement Program (2010-2016) was queried for patients with severe TBI of the head. Patients were compared by age (age < 65 and age ≥ 65 years) and survival after WLST (survivors versus non-survivors) at hospitalization discharge. A multivariable logistic regression model was used for analysis. From 1,403,466 trauma admissions, 328,588 (23.4%) patients had severe TBI. Age ≥ 65 years was associated with increased WLST (odds ratio: 1.76, confidence interval: 1.59-1.94, P < 0.001), whereas nonwhite race was associated with decreased WLST (odds ratio: 0.60, confidence interval: 0.55-0.65, P < 0.001). Compared with non-survivors of WLST, survivors were older (74 vs 61 years, P < 0.001) and more likely to have comorbidities such as hypertension (57% vs 38.5%, P < 0.001). Age ≥ 65 years was an independent risk factor for WLST, and nonwhite race was associated with decreased WLST. Patients surviving until discharge after WLST decision were older (≥74 years) and had multiple comorbidities.

Entities:  

Mesh:

Year:  2020        PMID: 32077410

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  2 in total

1.  Predictors for Withdrawal of Life-Sustaining Therapies in Patients With Traumatic Brain Injury: A Retrospective Trauma Quality Improvement Program Database Study.

Authors:  Belinda S DeMario; Samuel P Stanley; Evelyn I Truong; Husayn A Ladhani; Laura R Brown; Vanessa P Ho; Michael L Kelly
Journal:  Neurosurgery       Date:  2022-04-28       Impact factor: 5.315

2.  Effect of Ulinastatin Combined with Xingnaojing Injection on Severe Traumatic Craniocerebral Injury and Its Influence on Oxidative Stress Response and Inflammatory Response.

Authors:  Zexin An; Yong Yin; Lei Zhang; Bo Wang; Tao Cui; Meng Li; Jianwei Zhuo; Jing Zhang; Kai Wang; Wenwen Zhang; Meng Ji; Jilin Sun; Yinong Xu
Journal:  Biomed Res Int       Date:  2022-01-10       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.